前沿生物双靶点siRNA药物FB7011带来IgA肾病治疗新方案

Group 1 - The 18th International IgA Nephropathy Symposium (IIgANN 2025) will be held in Prague, Czech Republic, from September 17 to 20, 2025, where Frontier Biotech will present preclinical data for its dual-target small nucleic acid drug FB7011 for the first time [1] - FB7011 targets key proteins MASP-2 and CFB in the complement system, showing over 95% inhibition of both targets in a single subcutaneous dose (6 mg/kg) in crab-eating monkeys, with effects lasting over 12 weeks, indicating potential for dosing every 4-6 months in humans [1] - FB7011 demonstrated significant improvement in disease progression indicators (uTP, uPCR, and eGFR) in crab-eating monkey models of IgA nephropathy, with low off-target risk and good safety profile [1] Group 2 - Another drug, FB7013, shows promising preclinical data as a first-in-class targeted MASP-2 small nucleic acid drug, with sustained target protein reduction for 16 weeks after a single subcutaneous dose in healthy monkeys, and effective disease progression inhibition in crab-eating monkey models after 8 weeks [2] - Both FB7011 and FB7013 have novel mechanisms of action, with no similar small nucleic acid drugs approved or in clinical trials globally, presenting significant differentiation advantages [2] - The International IgA Nephropathy Network expert committee highlighted the importance of FB7013 as the first siRNA drug targeting MASP-2, with potential to change treatment regimens if clinical data supports its efficacy [3] Group 3 - IgA nephropathy is the most common primary glomerulonephritis globally, with over 10.2 million patients expected by 2030, and a significant burden on healthcare systems due to high treatment costs [4] - The urgent need for safe, effective, and convenient treatments for IgA nephropathy presents a vast market opportunity, which Frontier Biotech aims to address with its dual-target small nucleic acid drug [4] - The company is accelerating clinical development of its products to provide breakthrough treatment options for this "silent epidemic" [4]